Overall verdict
Neutral
3.9/10
1-year performance
+176.87%
Score breakdown
Up 176.9% over 1 year, 71% of the 52-week range.
Strongest: Financial strength 5.8/10. Weakest: Shareholder return 0.0/10.
25 analysts, target +0.5% vs the price.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.
Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC ; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial ; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Mark Goldsmith
Founded
2014
Employees
883
Revenue / employee
0 USD
Next earnings
February 25, 2027 (estimated)
Institutional holders
- FMR LLC7.12%
- GEODE CAPITAL MANAGEMENT, LLC1.85%
- Bank of New York Mellon Corp0.33%
- Rest of the register90.70%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
224.31 USD
52-week low
62.29 USD
1-year performance
176.87%
Rising
Year-to-date performance
120.87%
Rising
Drawdown
-20.94%
Marked drawdown
Position in the 52-week range
71% of range
Gross margin 90.3%, the company loses 946.8% of its revenue, ROIC -70.0%, ROE -93.6%.
Net margin
-946.82%
Negative
Sector -13.47%|S&P 13.40%
Gross margin
90.31%
Fair
Return on equity (ROE)
-93.56%
Negative
Sector -17.71%|S&P 17.06%
Return on invested capital (ROIC)
-70.02%
Negative
Free cash flow margin (FCF)
-729.31%
Negative
Revenue to net income
Growth
0.0/10-100.0% a year over 5.
Revenue (trailing 12 months)
198M USD
Revenue growth (1y)
—
Revenue growth (3y)
-100.00%
Declining
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 31.0x|S&P 23.6x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
—
N/A (loss)
Sector 17.4x|S&P 15.5x
PEG
—
Sector 0.53|S&P 0.91
Market cap
38.4Md USD
Financial strength
5.8/10Cash covers 301.4% of the debt, no net debt (net cash).
Net debt / EBITDA
—
Gearing (net debt / equity)
-101.60%
Net cash
Cash
3.7Md USD
Cash / market cap
9.52%
Solid
Cash / total debt
301.42%
Net cash
Interest coverage
-20.6x
Stretched
Net debt
-2.4Md USD
Equity
2.4Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 193.06 USD
- MM20189.72
- MM50196.48
- MM200158.71
- RSI 1450.3
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+6.17%
200-day average slope, 3 months
+30.79%
50-day average slope, 1 month
-3.48%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
4.34 % per day
Volatility change
+61.98%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -8.38 (21) | -8.30 (22) | 625 (19) | -1 514 (6) | -1 736 (17) |
| 2027 | -2.97 (22) | -3.10 (23) | 2 025 (23) | -682 (7) | -618 (20) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 9, 2026.
Same sub-industry: 416 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARGX | 6.6 | 6.1 | 60.3Md USD | 38.9x | 32.8 % | 81.8 % | 23.3 % | -4.1x | 1.8 % | 16.9 % | ||
| 2 | REGN | 6.4 | 6.1 | 99.2Md USD | 21.2x | 28.5 % | 36.3 % | 13.9 % | -1.3x | 3.9 % | 47.3 % | ||
| 3 | ABBV | 6.1 | 5.0 | 521Md USD | 50.8x | 15.6 % | 10.3 % | 16.1 % | 2.2x | 3.6 % | 34.7 % | ||
| 4 | VRTX | 5.6 | 4.1 | 139Md USD | 35.2x | 30.5 % | 10.4 % | 17.5 % | -0.9x | 2.3 % | 29.2 % | ||
| 5 | AMGN | 5.5 | 5.3 | 253Md USD | 27.2x | 24.1 % | 8.1 % | 14.7 % | 2.9x | 3.8 % | 44.7 % | ||
| 6 | CSL | 4.6 | 3.7 | 65.9Md USD | Not meaningful (loss) | -15.6 % | -2.8 % | -8.9 % | 1.8x | 4.3 % | 14.8 % | ||
| 7 | GILD | 4.2 | 2.9 | 211Md USD | Not meaningful (loss) | -12.4 % | 6.7 % | -9.6 % | 1.1x | 6.5 % | 43.1 % | ||
| 8 | RVMD | 3.9 | 0.9 | 38.4Md USD | Not meaningful (loss) | -946.8 % | — | -70.0 % | — | -3.8 % | 176.9 % | ||
| 9 | MRNA | 3.3 | 1.3 | 101Md USD | Not meaningful (loss) | -110.5 % | 29.2 % | -26.5 % | 0.4x | -2.0 % | 896.8 % |
